Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.

@article{Shi2019SafetyAA,
  title={Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.},
  author={Yuankai Shi and Hang Su and Yongping Song and Wenqi Jiang and Xiuhua Sun and Wenbin Qian and Wei Zhang and Yuhuan Gao and Zhengming Jin and Jianfeng Zhou and Chuan Jin and Liqun Zou and Lugui Qiu and Wei Li and Jianmin Yang and Ming Xun Hou and Shan Zeng and Qingyuan Zhang and Jianda Hu and Hui Zhou and Yan Xiong and Peng Liu},
  journal={The Lancet. Haematology},
  year={2019},
  volume={6 1},
  pages={
          e12-e19
        }
}
BACKGROUND Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD-1 and its ligands. We aimed to assess the activity and safety profile of sintilimab in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. METHODS In this ongoing, single-arm, phase 2 study, we recruited patients with histopathologically diagnosed classical Hodgkin lymphoma that was relapsed or refractory after two or more… CONTINUE READING
BETA
6
Twitter Mentions